Deeny M, Hawthorn R, McKay Hart D
Division of Obstetrics and Gynaecology, Stobhill General Hospital, Glasgow, UK.
Postgrad Med J. 1991 May;67(787):450-4. doi: 10.1136/pgmj.67.787.450.
This double-blind, randomized, crossover study compared the efficacy and safety of danazol (100 mg twice daily) with matching placebo in the treatment of severe premenstrual syndrome. Nineteen patients were randomly allocated to receive danazol for 3 months followed by placebo, and 18 to receive treatment in the reverse order. Assessments of overall condition showed improvement to be statistically significantly more likely with danazol than with placebo (P less than 0.001) after 3 months' treatment. Furthermore, daily visual analogue scale assessments demonstrated statistically significantly better premenstrual scores with danazol in comparison to placebo for breast discomfort, irritability, depression, anxiety, mood swings, crying, depressed libido and abdominal swelling. It is concluded that danazol provides effective and generally well tolerated treatment for severe premenstrual syndrome.
这项双盲、随机、交叉研究比较了达那唑（每日两次，每次100毫克）与匹配安慰剂治疗重度经前综合征的疗效和安全性。19名患者被随机分配接受达那唑治疗3个月，随后接受安慰剂治疗，18名患者接受相反顺序的治疗。对整体状况的评估显示，治疗3个月后，达那唑治疗组的改善在统计学上比安慰剂组更显著（P小于0.001）。此外，每日视觉模拟量表评估显示，与安慰剂相比，达那唑在乳房不适、易怒、抑郁、焦虑、情绪波动、哭泣、性欲减退和腹部肿胀的经前评分方面在统计学上显著更好。结论是，达那唑为重度经前综合征提供了有效且耐受性良好的治疗方法。
